Anadys Pharmaceuticals (ANDS) Posts Wider than Expected Q3 Loss
Tweet Send to a FriendGet Alerts ANDS Hot Sheet
Price: $3.70 --0%
EPS Growth %: -45.5%
Financial Fact:
Total other income, net: 523K
Today's EPS Names:
ANF, DXLG, FL, More
EPS Growth %: -45.5%
Financial Fact:
Total other income, net: 523K
Today's EPS Names:
ANF, DXLG, FL, More
Trade ANDS Now!
Anadys Pharmaceuticals, Inc. (NASDAQ: ANDS) reported Q3 EPS of ($0.16), $0.02 worse than the analyst estimate of ($0.14).
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Abercrombie & Fitch Co. (ANF) Misses Q1 EPS by 4c; Guides FY Below Views
- Ross Stores, Inc. (ROST) Reports In-Line Q1 EPS, Raises Guidance
- Aeropostale, Inc. (ARO) Tops Q1 EPS by 1c; Guide for Wide Q2 Loss
Create E-mail Alert Related Categories
Earnings
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
